login
register
Home
Getting Started
ChartMill Overview
Growth Traders
Technical Swing Traders
Long Term Investors
Tools
Stock Screener
Stock Charts
Full Screen Stock Charts
Market Monitor
Sectors
Earnings
Analyzer
Insider Trading
Up- and Downgrades
Stock Market
Top Gainers and Losers
New 52 Week High and Low
Gap Up and Gap Down
Most Active
Premarket Movers
After-Hours Movers
Earnings Calendar
USA Market Overview
Canada Market Overview
Europe Market Overview
Trading Ideas
News
Blog
Documentation
Documentation Center
Videos
Indicators
Properties
Screener Market data
Popular Articles
Bull Flags
Relative Strength
Pocket Pivots
Support and Resistance
RSI Indicator
MACD Indicator
Piotroski F-score
Squeeze Plays
Weinstein
Technical Breakout Setups
Trading Tips
Premarket Movers
Gap Up Stocks
Best Dividend Stocks
Bullish Engulfing Pattern
Ascending Triangle Pattern
Swing Trading
All articles ...
Subscriptions
Swing Trading Course
Account
Disclaimer
Affiliate
Contact
Privacy
MERCK & CO. INC. (MRK) Stock News
USA
-
New York Stock Exchange
- NYSE:MRK -
US58933Y1055
-
Common Stock
105.66
USD
+5.26 (+5.24%)
Last: 11/25/2025, 8:04:00 PM
105.44
USD
-0.22 (-0.21%)
Pre-Market:
11/26/2025, 7:38:22 AM
Overview
Stock Chart
Technical Analysis
Fundamental Analysis
Analyst Ratings
Earnings Estimates
Financials
Ownership
News
MRK Latest News, Press Relases and Analysis
All
Press Releases
8 days ago - By: Chartmill
- Mentions:
FCX
ALB
DECK
PCAR
...
Which S&P500 stocks are moving on Tuesday?
8 days ago - By: Chartmill
- Mentions:
MDT
HD
NFLX
Which S&P500 stocks have an unusual volume on Tuesday?
an hour ago - By: Merck & Co., Inc.
Merck to Participate in the Citi 2025 Global Healthcare Conference
an hour ago - By: Merck Sharp & Dohme
Merck to Participate in the 8th Annual Evercore ISI HealthCONx Conference
2 days ago - By: BioMedWire
- Mentions:
OTLC
IOVA
LLY
JNJ
Biotech Valuations Rise as New Clinical Platforms Show Progress
2 days ago - By: Merck & Co., Inc.
Merck Data to be Presented at ASH 2025 Annual Meeting Showcase Continued Advancements in Hematology Pipeline and Novel Therapeutic Approaches
5 days ago - By: Merck & Co., Inc.
Merck Recommends Rejection of Tutanota’s “Mini-Tender” Offer
5 days ago - By: Merck & Co., Inc.
FDA Approves KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), Each with Padcev® (enfortumab vedotin-ejfv), as Perioperative Treatment for Adults with Cisplatin-Ineligible Muscle-Invasive Bladder Cancer
5 days ago - By: Zacks Investment Research
- Mentions:
AZN
ADMA
EDIT
AZN Wins FDA Nod for Expanded Use of Rare Disease Drug, Koselugo
5 days ago - By: Zacks Investment Research
- Mentions:
PFE
AZN
BMY
PFE's New & Acquired Drugs Drive Non-COVID Comeback as LOE Test Looms
5 days ago - By: Zacks Investment Research
- Mentions:
V
SO
CHCI
CMTV
The Zacks Analyst Blog Highlights Visa, Merck, Southern Company, Community Bancorp and Comstock
5 days ago - By: The Motley Fool
- Mentions:
SPY
GS
KO
PFE
...
Goldman Sachs Just Delivered Bad News for U.S. Investors ... Sort Of. Here's What You Need to Know.
6 days ago - By: Zacks Investment Research
- Mentions:
V
SO
ETR
TTWO
...
Top Analyst Reports for Visa, Merck & Southern Company
6 days ago - By: Zacks Investment Research
- Mentions:
GILD
ADMA
ARQT
MRK HIV Regimen Meets Goal in New Study, Gains EU Nod for Keytruda SC
6 days ago - By: The Motley Fool
- Mentions:
CDTX
Merck Is Buying Cidara Therapeutics for $9.2 Billion. Is This the Boost the Lagging Drugmaker Needs?
6 days ago - By: Zacks Investment Research
Here's Why Merck (MRK) is a Strong Value Stock
6 days ago - By: Stocktwits
- Mentions:
UNH
BMY
NVS
Big Pharma Layoff Wave Extends Into Next Year: UNH, Merck, BMS, Novartis File New WARN Notices
7 days ago - By: Benzinga
- Mentions:
GILD
Merck's Investigational Two-Drug Regime Matches Gilead's Three-Drug Tablet For HIV Treatment
7 days ago - By: Stocktwits
- Mentions:
GILD
Merck Says Its Two-Drug Regimen For HIV Treatment Proven Non-Inferior To Gilead’s Biktarvy In Study
7 days ago - By: Zacks Investment Research
- Mentions:
JNJ
UTHR
Merck Stock Rise as New PAH Drug Winrevair Meets Goal in Another Study
7 days ago - By: Merck & Co., Inc.
Merck Announces Positive Topline Results from the Pivotal Phase 3 Trial Evaluating Investigational, Once-Daily, Oral, Two-Drug, Single-Tablet Regimen of Doravirine/Islatravir (DOR/ISL) in Treatment-Naïve Adults with HIV-1 Infection
7 days ago - By: Merck & Co., Inc.
European Commission Approves Subcutaneous Administration of KEYTRUDA® (pembrolizumab) for All Adult Indications Approved in the European Union
8 days ago - By: Benzinga
- Mentions:
MU
TPL
DIA
WDC
...
Tech Stocks Drop, Pharma Gains As Sector Rotation Picks Up: What's Moving Markets Tuesday?
8 days ago - By: Chartmill
- Mentions:
FCX
ADM
DECK
PCAR
...
Uncover the latest developments among S&P500 stocks in today's session.
8 days ago - By: Chartmill
- Mentions:
FCX
INCY
MOH
MDT
...
Top S&P500 movers in Tuesday's pre-market session
9 days ago - By: Chartmill
MERCK & CO. INC. (NYSE:MRK): A Value Investment with Strong Fundamentals
15 days ago - By: Chartmill
- Mentions:
DVN
APP
CI
ALGN
...
Exploring the top movers within the S&P500 index during today's session.
15 days ago - By: Chartmill
- Mentions:
DVN
APP
NKE
ALGN
...
What's going on in today's session: S&P500 movers
20 days ago - By: Chartmill
Merck & Co. Inc. (NYSE:MRK) Presents a Compelling Case for Dividend Investors
Please enable JavaScript to continue using this application.